This page shows the latest vedolizumab news and features for those working in and with pharma, biotech and healthcare.
FDA panel backs Takeda's inflammatory bowel disease drug. Vedolizumab on course for US approval to treat Crohn's disease and ulcerative colitis. ... Takeda's Millennium Pharmaceuticals unit took a step closer to US approval for one of its top pipeline
FDA grants priority review to Takeda's colitis drug. Accelerates review time for vedolizumab. ... One of Takeda's top pipeline prospects - vedolizumab for ulcerative colitis ( UC) - has been given a priority review by the US Food and Drug Administration (
Phase III data raise hopes for Takeda's vedolizumab. Bowel disease drug shows efficacy in ulcerative colitis and Crohn's disease. ... Data from phase III trials of Takeda's inflammatory bowel disease ( IBD) drug vedolizumab suggests the company's
Takeda files IBD drug vedolizumab in Europe. Potential safer alternative to TNF blockers like Remicade and Humira. ... Takeda has filed for approval in Europe of inflammatory bowel disease ( IBD) drug vedolizumab, one of its key pipeline drugs.
The CHMP also gave the nod to Takeda's locally-targeted drug for ulcerative colitis and Crohn's disease - Entyvio ( vedolizumab). ... Vedolizumab's regulatory review in the US has been delayed by a few months, but has been backed by an FDA advisory
There has also been a delay in the US for regulatory review of its new ulcerative colitis candidate vedolizumab although it remains on track for Crohn's disease.
There's prostate cancer drug orteronel ( TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel ( TAK-700),